{"id":"NCT02288247","sponsor":"Astellas Pharma Europe Ltd.","briefTitle":"A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone","officialTitle":"A Randomized, Double Blind, Placebo-Controlled, Phase IIIb Study of the Efficacy and Safety of Continuing Enzalutamide in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Patients Treated With Docetaxel Plus Prednisolone Who Have Progressed on Enzalutamide Alone","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-12-01","primaryCompletion":"2020-04-30","completion":"2024-03-15","firstPosted":"2014-11-11","resultsPosted":"2021-12-15","lastUpdate":"2025-04-08"},"enrollment":688,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Metastatic Castration Resistant Prostate Cancer"],"interventions":[{"type":"DRUG","name":"Enzalutamide","otherNames":["Xtandi","ASP9785"]},{"type":"DRUG","name":"Docetaxel","otherNames":[]},{"type":"DRUG","name":"Prednisolone","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Enzalutamide","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study was to understand if there was benefit in continued treatment with a medicine called enzalutamide, when starting treatment with docetaxel and prednisolone (a standard chemotherapy for prostate cancer), after the prostate cancer had gotten worse when treated with enzalutamide alone.","primaryOutcome":{"measure":"Progression Free Survival (PFS)","timeFrame":"From date of randomization to the earliest of either documented disease progression (median duration: 35 weeks)","effectByArm":[{"arm":"Enzalutamide","deltaMin":9.53,"sd":null},{"arm":"Placebo","deltaMin":8.28,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.027"}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":13},"locations":{"siteCount":89,"countries":["Austria","Belgium","Czechia","France","Germany","Greece","Italy","Netherlands","Norway","Poland","Russia","Spain","Sweden","Switzerland","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["36265504"],"seeAlso":["https://www.trialsummaries.com/Study/StudyDetails?id=14680&tenant=MT_AST_9011"]},"adverseEventsSummary":{"seriousAny":{"events":238,"n":687},"commonTop":["Fatigue","Asthenia","Back pain","Diarrhoea","Nausea"]}}